Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KURT W LESH

Allopathic & Osteopathic Physicians Family Medicine

NPI
1780629824
CMS profile
216969
Location
COLORADO SPGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$5,004.34

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,002.43 132
Travel and Lodging $1,896.66 6
Education $105.25 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KURT W LESH

NPI 1780629824 · CMS profile ID 216969

Allopathic & Osteopathic Physicians / Family Medicine

COLORADO SPGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780629824?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KURT W LESH, NPI 1780629824, CMS profile ID 216969. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780629824?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KURT W LESH, NPI 1780629824, CMS profile ID 216969. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780629824?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KURT W LESH, NPI 1780629824, CMS profile ID 216969, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1780629824?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $5,004.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $10.9112/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685115147 CMS
Amgen Inc. $13.9712/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662615901 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1012/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700117653 CMS
Lilly USA, LLC $11.0612/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657956905 CMS
Amarin Pharma Inc. $16.2312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699266399 CMS
Amgen Inc. $13.8212/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662615873 CMS
Allergan Inc. $7.8011/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718209 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $89.6511/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700117649 CMS
Lilly USA, LLC $9.0511/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657977345 CMS
SANOFI-AVENTIS U.S. LLC $15.6711/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694290993 CMS
AstraZeneca Pharmaceuticals LP $20.5211/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685092971 CMS
Amarin Pharma Inc. $4.9611/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699252957 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.3111/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700117655 CMS
Amarin Pharma Inc. $5.7410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699241151 CMS
Amarin Pharma Inc. $18.4110/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699240697 CMS
Lilly USA, LLC $10.1110/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657974127 CMS
Horizon Therapeutics plc $18.1410/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691428801 CMS
Lilly USA, LLC $10.5310/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657956903 CMS
Allergan Inc. $5.0410/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718205 CMS
Amgen Inc. $97.4310/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662615885 CMS
E.R. Squibb & Sons, L.L.C. $11.9710/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651332899 CMS
Amarin Pharma Inc. $24.7210/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699227139 CMS
Amgen Inc. $12.2110/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662615897 CMS
AstraZeneca Pharmaceuticals LP $12.0709/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685815039 CMS
Lilly USA, LLC $9.4009/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657960293 CMS
AstraZeneca Pharmaceuticals LP $102.9209/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685829867 CMS
Janssen Pharmaceuticals, Inc $24.0109/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658913367 CMS
Allergan Inc. $13.1209/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718203 CMS
Amarin Pharma Inc. $4.0609/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699218435 CMS
Cranial Technologies, Inc $14.9009/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697185155 CMS
Janssen Pharmaceuticals, Inc $15.7209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658913363 CMS
Kowa Pharmaceuticals America, Inc. $11.1109/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630281949 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.8809/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700117657 CMS
PFIZER INC. $9.1209/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672858684 CMS
Astellas Pharma US Inc $99.9909/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655658313 CMS
W. L. Gore & Associates, Inc. $148.4809/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705064089 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.1308/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700117659 CMS
Amarin Pharma Inc. $4.7508/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699201349 CMS
Janssen Pharmaceuticals, Inc $23.7008/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658913359 CMS
AstraZeneca Pharmaceuticals LP $21.5908/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685330261 CMS
Amgen Inc. $14.5808/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662615869 CMS
Lilly USA, LLC $10.5308/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657960291 CMS
SANOFI-AVENTIS U.S. LLC $19.7008/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694085943 CMS
Allergan Inc. $785.6608/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718179 CMS
Allergan Inc. $140.7808/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718183 CMS
Allergan Inc. $132.9508/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718185 CMS
Allergan Inc. $178.6808/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718189 CMS
Allergan Inc. $86.0808/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718191 CMS
Allergan Inc. $301.0008/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718195 CMS
Allergan Inc. $301.0008/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670718197 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,004.34 140
PY2020 $1,265.97 64
PY2021 $764.58 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $25,582.06 14
PY2020 Principal investigator $235,448.51 139
PY2019 Recipient $1,742.78 4
PY2019 Principal investigator $194,140.22 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $7,815.45 12/31/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721316055
Principal investigator 1 AstraZeneca Pharmaceuticals LP $283.17 12/31/2020 Non-covered Recipient Entity
Clinical Research Advantage Inc
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736747725
Principal investigator 1 SANOFI US SERVICES INC. $796.00 12/22/2020 Non-covered Recipient Entity
Clinical Research Advantage Incorporation
A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744022057
Principal investigator 1 SANOFI US SERVICES INC. $796.00 12/22/2020 Non-covered Recipient Entity
Clinical Research Advantage Incorporation
A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744022065
Principal investigator 1 Eisai Inc. $75,000.00 12/08/2020 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE, INC.
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 749106049
Principal investigator 1 Allergan, Inc. $169.00 11/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721309881
Principal investigator 1 Allergan, Inc. $50.00 11/09/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721307097
Principal investigator 1 Allergan, Inc. $21.00 11/09/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721307099
Principal investigator 1 Allergan, Inc. $1,096.30 10/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721305819
Principal investigator 1 Allergan, Inc. $150.00 09/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721301039
Principal investigator 1 Allergan, Inc. $63.00 09/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721301041
Principal investigator 1 Allergan, Inc. $327.00 09/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721300915
Principal investigator 1 Allergan, Inc. $50.00 09/25/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721300637
Principal investigator 1 Allergan, Inc. $21.00 09/25/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721300641
Principal investigator 1 Allergan, Inc. $2,195.45 09/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721300517
Principal investigator 1 Allergan, Inc. $1,197.00 09/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721300521
Principal investigator 1 Allergan, Inc. $1,197.00 09/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721300523
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721299539
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721299607
Principal investigator 1 Allergan, Inc. $327.00 09/08/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721295855
Principal investigator 1 Allergan, Inc. $327.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721295219
Principal investigator 1 SANOFI US SERVICES INC. $1,797.00 08/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744062731
Principal investigator 1 SANOFI US SERVICES INC. $1,797.00 08/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744062759
Principal investigator 1 SANOFI US SERVICES INC. $796.00 08/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744062887
Principal investigator 1 SANOFI US SERVICES INC. $796.00 08/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744062917
Principal investigator 1 PFIZER INC. $2,275.00 08/27/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742921397
Principal investigator 1 Allergan, Inc. $327.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721292239
Principal investigator 1 Allergan, Inc. $100.00 08/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721288163
Principal investigator 1 Allergan, Inc. $100.00 08/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721288165
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063169
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063225
Principal investigator 1 SANOFI US SERVICES INC. $1,797.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063310
Principal investigator 1 SANOFI US SERVICES INC. $1,797.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063383
Principal investigator 1 SANOFI US SERVICES INC. $796.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063587
Principal investigator 1 SANOFI US SERVICES INC. $796.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063601
Principal investigator 1 SANOFI US SERVICES INC. $183.00 07/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063639
Principal investigator 1 Allergan, Inc. $1,930.40 07/22/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721286203
Principal investigator 1 Allergan, Inc. $339.12 07/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721283265
Principal investigator 1 SANOFI US SERVICES INC. $1,797.00 06/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064193
Principal investigator 1 SANOFI US SERVICES INC. $1,797.00 06/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064221
Principal investigator 1 SANOFI US SERVICES INC. $360.00 06/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065301
Principal investigator 1 SANOFI US SERVICES INC. $294.00 06/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744066201
Principal investigator 1 Allergan, Inc. $50.00 06/17/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280519
Principal investigator 1 Allergan, Inc. $50.00 06/17/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280521
Principal investigator 1 Allergan, Inc. $150.00 06/17/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280551
Principal investigator 1 Allergan, Inc. $225.00 06/17/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280555
Principal investigator 1 Allergan, Inc. $800.00 06/17/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280563
Principal investigator 1 Allergan, Inc. $1,641.60 06/17/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280567
Principal investigator 1 Allergan, Inc. $100.00 06/11/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721279241
Principal investigator 1 Allergan, Inc. $100.00 06/11/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721279243
Principal investigator 1 Allergan, Inc. $21.00 06/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721278201
Principal investigator 1 Allergan, Inc. $50.00 06/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721278207
Principal investigator 1 SANOFI US SERVICES INC. $2,046.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064395
Principal investigator 1 SANOFI US SERVICES INC. $2,046.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064497
Principal investigator 1 SANOFI US SERVICES INC. $2,046.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064537
Principal investigator 1 SANOFI US SERVICES INC. $294.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065119
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065287
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065314
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065341
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065429
Principal investigator 1 SANOFI US SERVICES INC. $177.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065463
Principal investigator 1 SANOFI US SERVICES INC. $360.00 05/31/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744065585
Principal investigator 1 Allergan, Inc. $1,641.60 05/29/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721277903
Principal investigator 1 Allergan, Inc. $3,200.52 05/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273977
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 04/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744063929
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 04/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064261
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 04/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064365
Principal investigator 1 SANOFI US SERVICES INC. $294.00 04/30/2020 Non-covered Recipient Entity
Clinical Research Advantage,Inc
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744064681
Principal investigator 1 Allergan, Inc. $3,187.25 04/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721272633
Principal investigator 1 Allergan, Inc. $1,738.50 04/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721272649
Principal investigator 1 Allergan, Inc. $200.00 04/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721268191
Principal investigator 1 Allergan, Inc. $275.00 04/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721268197
Principal investigator 1 Allergan, Inc. $800.00 04/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721268223
Principal investigator 1 SANOFI US SERVICES INC. $294.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072075
Principal investigator 1 SANOFI US SERVICES INC. $294.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072093
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072140
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072179
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072197
Principal investigator 1 SANOFI US SERVICES INC. $294.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072237
Principal investigator 1 SANOFI US SERVICES INC. $294.00 03/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072243
Principal investigator 1 Allergan, Inc. $5,638.25 03/19/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721266221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,397.90 03/11/2020 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724457469
Principal investigator 1 Allergan, Inc. $8,036.00 03/03/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721261787
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744070677
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744070779
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744070831
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071099
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071110
Principal investigator 1 SANOFI US SERVICES INC. $294.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071138
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071169
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071185
Principal investigator 1 SANOFI US SERVICES INC. $709.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071227
Principal investigator 1 SANOFI US SERVICES INC. $709.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071241
Principal investigator 1 SANOFI US SERVICES INC. $1,416.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071443
Principal investigator 1 SANOFI US SERVICES INC. $1,416.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071457
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071493
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 02/29/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071503
Principal investigator 1 Allergan, Inc. $700.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721259957
Principal investigator 1 Allergan, Inc. $100.00 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259237
Principal investigator 1 Allergan, Inc. $175.00 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259255
Principal investigator 1 Allergan, Inc. $800.00 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259273
Principal investigator 1 Allergan, Inc. $7,742.50 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259353
Principal investigator 1 Allergan, Inc. $50.00 02/20/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721258643
Principal investigator 1 Allergan, Inc. $50.00 02/20/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721258645
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,300.00 02/18/2020 Non-covered Recipient Entity
Clinical Research Advantage Inc
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736750173
Principal investigator 1 Allergan, Inc. $700.00 02/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721255543
Principal investigator 1 Allergan, Inc. $700.00 02/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721255647
Principal investigator 1 Allergan, Inc. $200.00 02/03/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721255073
Principal investigator 1 Allergan, Inc. $200.00 02/03/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721255077
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069693
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069699
Principal investigator 1 SANOFI US SERVICES INC. $1,187.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069705
Principal investigator 1 SANOFI US SERVICES INC. $294.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069741
Principal investigator 1 SANOFI US SERVICES INC. $294.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069745
Principal investigator 1 SANOFI US SERVICES INC. $294.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069769
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069793
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069811
Principal investigator 1 SANOFI US SERVICES INC. $1,255.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069823
Principal investigator 1 SANOFI US SERVICES INC. $709.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069861
Principal investigator 1 SANOFI US SERVICES INC. $2,046.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069895
Principal investigator 1 SANOFI US SERVICES INC. $2,046.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069911
Principal investigator 1 SANOFI US SERVICES INC. $1,416.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069933
Principal investigator 1 SANOFI US SERVICES INC. $1,416.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069949
Principal investigator 1 SANOFI US SERVICES INC. $1,416.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744069969
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071785
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071797
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071835
Principal investigator 1 SANOFI US SERVICES INC. $1,173.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744071842
Principal investigator 1 SANOFI US SERVICES INC. $177.00 01/31/2020 Non-covered Recipient Entity
East Valley Family Phys
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea No dispute reported 06/30/2026 744072731
Principal investigator 1 Merck Sharp & Dohme Corporation $1,040.00 01/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC. COLORADO SPRINGS FAMILY PRACTICE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 740741495
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721252643
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721252865
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721253171
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721253307
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721253677
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 01/28/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC. COLORADO SPRINGS FAMILY PRACTICE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 740741497
Principal investigator 1 Allergan, Inc. $7,742.50 01/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721250639
Principal investigator 1 Allergan, Inc. $50.00 01/21/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721249465
Principal investigator 1 Allergan, Inc. $50.00 01/21/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721249467